University of Gothenburg
  2. About
  3. Find staff
  4. Gudmundur Johannsson

Gudmundur Johannsson

Professor/ Chief Physician

Department of Internal Medicine and Clinical Nutrition
Telephone
+46 31-342 70 52
Mail
gudmundur.johannsson@medic.gu.se
Visiting address
Medicinaregatan 3, plan 5
413 90 Göteborg
Postal address
Box 428
405 30 Göteborg

Assistant Dean

Sahlgrenska Academy at University of Gothenburg
Mail
gudmundur.johannsson@medic.gu.se
Visiting address
Medicinaregatan 3
41390 Göteborg
Postal address
Box 400
40530 Göteborg

About Gudmundur Johannsson

Short biography

Professor of Endocrinology and Vice Dean at the Sahlgrenska Academy (Faculty of Medicin), University of Gothenburg

Senior Consultant at the Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden.

Head of Department of Endocrinology at the Sahlgrenska University Hospital 2000 – 2011, Deputy Director, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg between 2015-2018, Deputy Director Institute of Medicine, Sahlgrenska Academy between 2018-2023 and Vice Dean Sahlgrenska Academy, University of Gothenburg from 2024.

Visiting Professor at the University of New South Wales, Sydney, Australia from 2001 to 2003. Board member and past-president of the Growth Hormone Research Society, board member of the Pituitary Society and member of the steering committee of European Reference Network on Rare Endocrine Conditions in the European Union.

Education

Teacher of medical student during their clinical part of the medical program.

Course leader and then examiner for internal medicine at the medical program.

Vice prefect (director) responsible for education at the Institute of Medicine between 2018-2023 and since January 2024 Vice Dean at Sahlgrenska Academy with responsibility for education.

Research

Gudmundur Johannsson and his team have made significant contributions in the field of endocrinology, particularly in understanding and managing pituitary tumors and its consequences and related conditions.

They identified putative biomarkers for tumor aggressiveness through the Gothenburg Pituitary Tumor (GoPT) study, discovering genetic, epigenetic, and proteomic markers associated with tumor progression.

In glucocorticoid replacement therapy for adrenal insufficiency, they conducted trials to refine dosing and identified biomarkers for exposure and action. Their studies have also highlighted risks of adrenal insufficiency for morbidity and mortality and developed new methods that may reduce these risks.

The pituitary group in Gothenburg is well known for their contribution to the understanding of the importance of growth hormone (GH) in adult patients with pituitary hormone deficiency and GH deficiency.

The group has also significantly contributed to the understanding of disease burden and outcome in rare patients groups with functioning pituitary tumours such as Cushing’s disease and acromegaly.

In collaboration with Centre for Person-centred Care – GPCC, University of Gothenburg, a nurse-led, patient-centered care model for pituitary tumor patients, now partially implemented in clinical practice.